JP2023515618A5 - - Google Patents

Info

Publication number
JP2023515618A5
JP2023515618A5 JP2022552206A JP2022552206A JP2023515618A5 JP 2023515618 A5 JP2023515618 A5 JP 2023515618A5 JP 2022552206 A JP2022552206 A JP 2022552206A JP 2022552206 A JP2022552206 A JP 2022552206A JP 2023515618 A5 JP2023515618 A5 JP 2023515618A5
Authority
JP
Japan
Prior art keywords
compound according
compound
alkyl
independently
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552206A
Other languages
English (en)
Japanese (ja)
Other versions
JP7901883B2 (ja
JP2023515618A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020173 external-priority patent/WO2021174176A1/en
Publication of JP2023515618A publication Critical patent/JP2023515618A/ja
Publication of JP2023515618A5 publication Critical patent/JP2023515618A5/ja
Application granted granted Critical
Publication of JP7901883B2 publication Critical patent/JP7901883B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552206A 2020-02-28 2021-02-28 核酸スプライシングを調節するためのピリダジン誘導体 Active JP7901883B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062983537P 2020-02-28 2020-02-28
US62/983,537 2020-02-28
US202063007134P 2020-04-08 2020-04-08
US63/007,134 2020-04-08
US202063040474P 2020-06-17 2020-06-17
US63/040,474 2020-06-17
US202063072781P 2020-08-31 2020-08-31
US63/072,781 2020-08-31
US202063126491P 2020-12-16 2020-12-16
US63/126,491 2020-12-16
PCT/US2021/020173 WO2021174176A1 (en) 2020-02-28 2021-02-28 Pyridazine dervatives for modulating nucleic acid splicing

Publications (3)

Publication Number Publication Date
JP2023515618A JP2023515618A (ja) 2023-04-13
JP2023515618A5 true JP2023515618A5 (enExample) 2025-08-06
JP7901883B2 JP7901883B2 (ja) 2026-08-07

Family

ID=75278334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552203A Pending JP2023515617A (ja) 2020-02-28 2021-02-28 核酸スプライシングを調節するためのピリダジン誘導体
JP2022552206A Active JP7901883B2 (ja) 2020-02-28 2021-02-28 核酸スプライシングを調節するためのピリダジン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022552203A Pending JP2023515617A (ja) 2020-02-28 2021-02-28 核酸スプライシングを調節するためのピリダジン誘導体

Country Status (11)

Country Link
US (2) US20230365526A1 (enExample)
EP (2) EP4110774A1 (enExample)
JP (2) JP2023515617A (enExample)
KR (2) KR20220157407A (enExample)
CN (2) CN115551847A (enExample)
AU (3) AU2021228286A1 (enExample)
BR (2) BR112022017089A2 (enExample)
CA (2) CA3169667A1 (enExample)
IL (2) IL295954A (enExample)
MX (2) MX2022010637A (enExample)
WO (2) WO2021174176A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102913697B1 (ko) * 2019-02-05 2026-01-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
KR102925385B1 (ko) 2019-02-06 2026-02-11 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
US20250333397A1 (en) * 2021-08-30 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
EP4426702A1 (en) * 2021-11-04 2024-09-11 Skyhawk Therapeutics, Inc. Condensed-pyrazine amine derivatives for treating sca3
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
EP4472969A4 (en) * 2022-01-31 2025-12-24 Novartis Ag PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTICANCER AGENTS
WO2023185468A1 (zh) * 2022-04-01 2023-10-05 浙江同源康医药股份有限公司 一类用作激酶抑制剂的化合物及其应用
AU2023327925A1 (en) * 2022-08-22 2025-02-20 Redx Pharma Limited Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer
WO2024182747A2 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2025211457A1 (ja) * 2024-04-05 2025-10-09 日本新薬株式会社 Cugリピートrnaとmbnlタンパクとの結合阻害化合物および医薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP3029035B1 (en) * 2013-07-31 2018-05-30 Sumitomo Chemical Company, Limited Tetrazolinone compound, and use thereof
MX381224B (es) * 2014-10-31 2025-03-12 Massachusetts Gen Hospital Potentes moduladores de gamma-secretasa.
EP3256126B1 (en) * 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA3119019C (en) * 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
WO2018140578A1 (en) * 2017-01-25 2018-08-02 President And Fellows Of Harvard College Non-fullerene solar panel acceptor compounds
CN111372611A (zh) * 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2020001425A (es) * 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
JP7270989B2 (ja) * 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
CA3090130A1 (en) * 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP2021521200A (ja) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド 癌の処置のための化合物
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲(江蘇)醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Similar Documents

Publication Publication Date Title
JP2023515617A5 (enExample)
JP2023515621A5 (enExample)
JP2023515620A5 (enExample)
JP2023520924A5 (enExample)
JP2023520925A5 (enExample)
JP2023520916A5 (enExample)
JP2024520481A5 (enExample)
IL295953A (en) Pyridazine derivatives regulate nucleic acid splicing
IL295956A (en) Heterocyclic amides and their use for modulating splicing
JP2021534124A5 (enExample)
JP2023513680A5 (enExample)
JP2022512482A5 (enExample)
JP2023553835A5 (enExample)
JP2021522276A5 (enExample)
JP2022544714A5 (enExample)
JP2021523225A5 (enExample)
CN109790135B (zh) 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
JP2007508305A5 (enExample)
JP2016515096A (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
JP2007507542A5 (enExample)
JP2009544602A5 (enExample)
JP2012236838A5 (enExample)
JP2012507522A5 (enExample)
JP2018504437A5 (enExample)
JP2022553841A5 (enExample)